WOBURN, Mass., March 25, 2011 /PRNewswire/ — Covaris
Incorporated today announced the introduction of the Bench-top
SF220 High Performance Formulation Processing System.
The SF220 system was designed to extend the company’s
ground-breaking Adaptive Focused Acoustics (AFA) technology to
higher volume sample processing. With the ability to process
sample volumes from microliters through tens of liters, larger
volume application areas such as Pre-clinical formulation, drug
delivery systems, and biological processes (such as cell lysis,
sonoporation, or transfection) can now “scale-up” the advantages of
the proven AFA technology.
The Covaris SF220 system provides a solution for the problem of
poorly soluble API’s using the proprietary Covaris AFA Technology.
For example, adoption of the AFA-based SF220 system for
preparation of DMPK formulations has been shown to improve quality
of the studies by increasing the bioavailability, while reducing
subjective content and improving operational efficiency.
Using AFA to accelerate dissolution can improve both the
quality and efficiency of the drug development process, with
unparalleled reproducibility, precision, and speed.
Demonstrated increases of solubility of over 90% have been
achieved, while concurrently reducing the process time from over 2
days of stirring to under 3 minutes, and increasing the available
API by over 2.5x due to a dramatic reduction in API degradation.
According to Jim Laugharn, Founder and CEO, “We at Covaris
are very excited about the introduction of the new systems to meet
the ‘pent-up demand’ our current customers have for processing
larger sample volumes with AFA technology.” At present,
Covaris has installed over 1,500 systems in over 30 countries
worldwide.
AFA has also been demonstrated to formulate monodisperse,
nano-emulsions with mean particle sizes of 20nm and an index below
0.100. Liposomes can be produced using a simp
‘/>”/>
